• Mirum Pharmaceuticals recently announced that Health Canada has authorized LIVMARLI (maralixibat) oral solution and tablet for treating cholestatic pruritus in PFIC patients aged 12 months and older, expanding its availability alongside its existing authorization for Alagille syndrome in Canada.
• This authorization is underpinned by the Phase 3 MARCH study, the largest randomized PFIC trial to date, which showed highly statistically significant pruritus reduction across multiple genetic PFIC types.
• We will now examine how Health Canada’s authorization of LIVMARLI for PFIC, supported by robust MARCH trial data, shapes Mirum’s investment narrative.

AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Mirum Pharmaceuticals' Investment Narrative?

To own Mirum, you really need to believe in its ability to convert niche liver disease approvals into durable commercial franchises, even while it remains only just on the cusp of profitability. Health Canada’s new LIVMARLI authorization in PFIC adds another brick to that thesis, reinforcing the idea of a de-risked clinical profile and a broadening global footprint rather than radically changing the story overnight. The most immediate catalysts still sit around execution against Mirum’s 2026 product revenue guidance of US$630 million to US$650 million, further label expansions in the US and Europe, and how efficiently the company can move from occasional quarterly profits to consistent earnings. On the risk side, the stock’s strong multi‑year run, premium sales multiples and ongoing losses keep expectations high, and make any stumble in uptake or margin progress more consequential.

However, one key risk tied to rising expectations and valuation is easy to underestimate. Despite retreating, Mirum Pharmaceuticals' shares might still be trading 14% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

Four Simply Wall St Community fair values for Mirum span roughly US$54 to about US$116, underlining how widely individual views can differ. Set against recent regulatory wins that could alter near term catalysts, this spread gives you a useful context to weigh enthusiasm about LIVMARLI’s expansion against execution risk and the company’s path toward sustained profitability.

Explore 4 other fair value estimates on Mirum Pharmaceuticals - why the stock might be worth 46% less than the current price!

Build Your Own Mirum Pharmaceuticals Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Mirum Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Mirum Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mirum Pharmaceuticals' overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Outshine the giants: these 27 early-stage AI stocks could fund your retirement.
• Find 52 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.